Compare Novartis AG (NVS) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X Defense Tech ETF — how do they compare? Novartis AG trades at $153.82 (market cap $298.18B), while Global X Defense Tech ETF trades at $69.48. The key difference: Novartis AG pays a 3.02% dividend while Global X Defense Tech ETF pays none, and Novartis AG is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SHLD | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $78.02 |
52-Week Low | $119.31 | $58.20 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
SHLD (Global X Defense Tech ETF) trades at $69.04, up 1.86% with bullish technical signals from moving averages but overbought RSI readings. The ETF benefits from institutional accumulation and positive sentiment around global defense spending increases. Recent news highlights multiple institutional investors increasing positions, while technical analysis shows strong support at $68 and resistance at $70.
Outlook remains positive given geopolitical tensions driving defense budgets higher, though overbought conditions suggest potential near-term consolidation. Key risks include political uncertainty and valuation concerns after recent gains. The ETF offers diversified exposure to defense technology with institutional confidence supporting the long-term thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
